

2018 TNET Society Foundational Meeting

New Trends of Neuroendocrine Tumors

時間：107年9月1日(星期六) 12:30~16:30

地點：台北市喜來登飯店 B2 喜廳 (地址：台北市忠孝東路一段 12 號)

共同主辦：台灣神經內分泌腫瘤學會籌備會、台灣胰臟醫學會

協辦單位：台灣諾華股份有限公司、法商益普生股份有限公司台灣分公司、輝瑞生醫股份有限公司

Time	Program/Topic	Speaker	Moderator
12:30~13:00	Registration		
13:00~13:10	Welcome Address & Founding Report	黃燦龍 教授 台灣神經內分泌腫瘤學會 籌備會召集人	
<i>First Session</i>			
13:10~13:35	Taiwan NETs Registration	蔡慧珍 教授 國家衛生研究院	陳立宗 教授 李金德 教授
13:35~13:50	Pathologic Diagnosis of Lung NETs	曾崧元 教授 台灣分子醫學會	王約翰 教授 孫家棟 教授
13:50~14:15	Functional NETs Associated with Endocrine System	施翔蓉 副教授 臺大醫院 代謝內分泌科	李建賢 教授 田郁文 教授
14:15~14:35	TNET Society General Assembly	全體會員	黃燦龍 教授
14:35~15:00	Coffee Break & 台灣神經內分泌腫瘤學會第一屆會員大會暨選舉		
<i>Second Session</i>			
15:00~15:25	Update Endoscopic Approach for P-NETs	鄭祖耀 副教授 臺大醫院 胃腸內科	王秀伯 教授 林肇堂 教授
15:25~15:50	Multidisciplinary Care of NETs in Taiwan	陳彥仰 副教授 高雄長庚紀念醫院 腫瘤內科	陳仁熙 教授 白禮源 教授
15:50~16:30	PRRT for Neuroendocrine Tumors	Prof. Hicks Rod Peter MacCallum Cancer Centre, Australia	施庭芳 教授 陳明晃 教授
16:30~16:40	Closing Remarks	黃燦龍 教授 台灣神經內分泌腫瘤學會 籌備會召集人	
17:00~20:00	台灣神經內分泌腫瘤學會第一屆第一次理監事會議		

學會教育積分：(申請中)

台灣外科醫學會、台灣內科醫學會、台灣消化系外科醫學會、台灣消化系內視鏡醫學會、台灣消化系醫學會、中華民國醫用超音波醫學會、中華民國放射線醫學會、中華民國癌症醫學會

Name: Hui-Jen Tsai, M.D. PhD.

Institute: National Institute of Cancer Research, National Health Research Institutes

Department of Internal Medicine, National Cheng Kung University Hospital

Address: No.367, Sheng Li Road, Tainan 70456, Taiwan R.O.C.

Tel: (O) 886-6-7000123 ext.65149

Fax : (O) 886-6-2083427

E-mail: hjtsai@nhri.org.tw

EDUCATION:

1989.9 - 1993.6 Bachelor. National Chiao Tung University, Hsinchu, Taiwan

1993.9 - 1998.6 M.D. Kaohsiung Medical University, Kaohsiung, Taiwan

2005.9 – 2014.7 PhD. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

POSTDOCTORAL TRAINING

2006.8 - 2008.1 Visiting Researcher, Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo

2003.8-2006.7 Attending Physician, Division of Hemato/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital.

2001.8 - 2003.7 Chief Resident, Department of Internal Medicine, Kaohsiung Medical University Hospital

1998.8 - 2001.7 Residency training, Department of Internal Medicine, Kaohsiung Medical University Hospital

1997.6 - 1998.5 Internship, Kaohsiung Medical University Hospital

LICENSURE AND CERTIFICATION:

1998 National Medical Board of Republic of China

2001 Specialist of Internal Medicine, Taiwan, R.O.C.

2003 Specialist of Hematology, Taiwan, R.O.C.

2004 Specialist of Medical Oncology, Taiwan, R.O.C.

HOSPITAL APPOINTMENTS:

2015.10 - Assistant Investigator, National Institute of Cancer Research, National Health Research Institutes

2011.1- 2015.9 Attending Physician, National Institute of Cancer Research, National Health Research Institutes

2003.8-2010.7 Attending Physician, Division of Hemato-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital

Publications:

1. Kuo SH, Tsai HJ, Lin CW, Yeh KH, Lee HW, Wei MF, Shun CT, Wu MS, Hsu PN, Chen LT, Cheng AL. [B cell-activating factor signalling pathway is associated with H. pylori independence in gastric MALT](#)

- [lymphoma without t\(11;18\)\(q21;q21\)](#). *J Pathol*. 2016 Nov 22. doi: 10.1002/path.4852. [Epub ahead of print] (IF:7.381, Journal ranking: Oncology: Q1)(共同作者)
2. Chen LT, Chen CT, Jiaang WT, Chen TY, Butterfield JH, Shih NY, Hsu JT, Lin HY, Lin SF, **Tsai HJ**. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia. *Mol Cancer Ther* 2016;15:2323-2333. (IF:5.579, Journal ranking: Oncology: Q1)(通訊作者)
 3. Chen JY, Lai YS, **Tsai HJ**, Kuo CC, Yen BL, Yeh SP, Sun HS, Hung WC. The oncometabolite R-2-hydroxyglutarate activates NF- κ B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. *Sci Rep* 2016;6:32428. (IF:5.228, Journal ranking: MULTIDISCIPLINARY SCIENCES: Q1)(共同作者)
 4. Chang JS, Chen LT, Shan YS, Lin SF, Hsiao SY, Tsai CR, Yu SJ, **Tsai HJ**. A comprehensive analysis in the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: a nation-wide cancer registry-based study from Taiwan. *Medicine* 2015, Jun;94(24):e969
 5. Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Wu MS, Liou JM, **Tsai HJ**, Tzeng YS, Cheng AL. Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. *Am J Surg Pathol*. 2015 Jun;39(6):761-6.
 6. Lai YS, Chen JY, **Tsai HJ**, Chen TY, Hung WC. The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. *Blood Cancer Journal* 2015;5:e313.
 7. **Tsai HJ**, Shih NY, Kuo SH, Cheng AL, Lin HY, Chen TY, Chang KC, Lin SF, Chang JS, Chen LT. AUY922 Effectively Targets against ABC-DLBCL and MALT Lymphoma Cells Harboring Genetic Alteration-Associated NF- κ B Activation. *Leukemia Lymphoma* 2015 Sep;56(9):2674-82..
 8. Hsiao HH, Liu YC, Wang HC, Wu CH, Cho SF, Hsu JF, **Tsai HJ**, Hsiao SY, Chang CS, Lin SF, Liu TC, Chuang WL, Yu ML. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. *Transpl Infect Dis*. 2014 Dec;16(6):1003-6
 9. **Tsai HJ**, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang JS, Chang MC, Su IJ. Long term results of a phase II trial with front-line concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. *European Journal of Haematology* 2015 Feb;94(2):130-7.
 10. Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Hsu C, Wu MS, Tzeng YS, **Tsai HJ**, Wang HP, Cheng AL. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. *Blood Cancer J* 2014 Jun 20;4:e220.
 11. **Tsai HJ**, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. Second Cancers in Patients with Neuroendocrine Tumors. *PLOS ONE* 2013;Dec 31;8(12):e86414.
 12. Kuo SH†, **Tsai HJ**†, Weng WH, Li CC, Yeh KH, Chen LT, Cheng AL. Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse. *Genes Chromosomes Cancer*. 2014 Feb;53(2):211-3. (†equal contribution)
 13. Kuo SH, Chen LT, Lin CW, Wu MS, Hsu PN, **Tsai HJ**, Chu CY, Tzeng YS, Wang HP, Yeh KH, Cheng AL. Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance. *Blood Cancer J*. 2013 Jul 12;3:e125. doi: 10.1038/bcj.2013.22.
 14. **Tsai HJ**, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The Epidemiology of Neuroendocrine Tumors in Taiwan: a Nation-wide Registry-based Study. *PLOS ONE* 2013;Apr 22;8(4):e62487
 15. Hsu YL, **Tsai HJ**, Chen YW, Lin CY, Lee CS, Chang CC. High metabolic lymphoma of the masticator space on FDG PET/CT image. *Annals of Nuclear Medicine and Molecular Imaging* 2011;24:144-145
 16. **Tsai HJ**, Kobayashi S, Izawa K, Ishida T, Umezawa K, Lin SF, Tojo A. Bioimaging analysis of nuclear factor- κ B activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its

- synergistic upregulation by tumor necrosis factor- α -stimulated changes to the microenvironment. *Cancer Sci* 2011;102:2014-21
17. [Kuo SH](#), [Weng WH](#), [Chen ZH](#), [Hsu PN](#), [Wu MS](#), [Lin CW](#), [Jeng HJ](#), [Yeh KH](#), [Tsai HJ](#), [Chen LT](#), [Cheng AL](#). Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-Independent Gastric MALT Lymphoma. *Genes Chromosomes Cancer*. 2011;50:908-21
 18. [Cho SF](#), [Liu YC](#), [Tsai HJ](#), [Lin SF](#). Myeloid Sarcoma Mimicking Nasopharyngeal Carcinoma. *J Clin Oncol*. 2011;29:e706-8.
 19. Yang MY, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, [Tsai HJ](#), Chang CS, Lin SF. Altered expression of circadian clock genes in human chronic myeloid leukemia. *J Biol Rhythms*. 2011;26:136-148
 20. Hsiao HH, Liu YC, [Tsai HJ](#), Hsu JF, Yang WC, Chang CS, Lin SF. Additional chromosome abnormalities in chronic myeloid leukemia. *Kaohsiung J Med Sci*. 2011;27:49-54
 21. [Hsiao HH](#), [Liu YC](#), [Tsai HJ](#), [Lee CP](#), [Hsu JF](#), [Lin SF](#). JAK2V617F mutation is associated with special alleles in essential thrombocythemia. *Leuk Lymphoma*. 2011 Mar;52(3):478-82. Epub 2011 Feb 1
 22. [Li CP](#), [Chen JS](#), [Chen LT](#), [Yen CJ](#), [Lee KD](#), [Su WP](#), [Lin PC](#), [Lu CH](#), [Tsai HJ](#), [Chao Y](#). A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. *Br J Cancer*. 2010 Oct 26;103(9):1343-8
 23. [Tai SY](#), [Wu IC](#), [Wu DC](#), [Su HJ](#), [Huang JL](#), [Tsai HJ](#), [Lu CY](#), [Lee JM](#), [Wu MT](#). Cigarette smoking and alcohol drinking and esophageal cancer risk in Taiwanese women. *World J Gastroenterol*. 2010 Mar 28;16(12):1518-21
 24. [Wu IC](#), [Wu DC](#), [Huang CC](#), [Lin HS](#), [Chen YK](#), [Tsai HJ](#), [Lu CY](#), [Chou SH](#), [Chou YP](#), [Li LH](#), [Tai SY](#), [Wu MT](#). Plasma decorin predicts the presence of esophageal squamous cell carcinoma. *Int J Cancer*. 2010;127:2138-46
 25. [Hsiao HH](#), [Tsai HJ](#), [Liu YC](#), [Lee CP](#), [Lin SF](#). Allo-SCT in a rare t(8;21) evolution of CML. *Bone Marrow Transplant* 2010;45:1365-6.

Conferences

1. [Tsai HJ](#). The epidemiology of neuroendocrine tumors in Taiwan. (invited speaker) 國際胰臟惡性腫瘤研討會 2014, Nov22, at 林口長庚紀念醫院.
2. [Tsai HJ](#), Lin MJ, Jiang WT, Chen CT, Hsu TA, Lin HY, Chen LT. BPR1J373, a novel multi-targeted tyrosine kinase inhibitor, effectively inhibits the growth of gastrointestinal stromal tumor *in vitro* and *in vivo*. The 73th annual meeting of Japanese Cancer Association. (oral presentation, travel award). Sep 25-27, 2014 at Yokohama, Japan.
3. [Tsai HJ](#), Wang MC, Lin SF, Chen YP, Hsiao HH, Kuo CY, Chen LT, Chen TY. Pegylated arginine deiminase (ADI-PEG20) in relapsed/refractory and/or elder acute myeloid leukemia: the preliminary result of phase II trial. (Poster) The 56th annual meeting of American Society of Hematology Dec 6-9, 2014 at San Francisco, US.
4. [Tsai HJ](#), Jiang WT, Chen CT, Hsu TA, Lin HY, Lin SF, Chen TY, Chen LT. Promising Novel Targeted Agent against *c-KIT* Driven Acute Myeloid Leukemia. 中華民國血液病學會暨中華民國血液及骨髓移植學會 104 年度聯合學術年會. Apr 18, 2015 at 台大國際會議廳(oral presentation)
5. [Tsai HJ](#), Chen LT, Shan YS, Lin SF, Hsiao SY, Tsai CR, Yu SJ, Chang JS. The changing incidence and survival of lung cancer in the era of targeted therapy: a nation-wide study from Taiwan. (poster) the 74th annual meeting of Japanese Cancer Association 2015, Oct 8-10, Nagoya, Japan.
6. [Tsai HJ](#), Jiang WT, Chen CT, Hsu TA, Lin HY, Kobayashi S, Tojo A, Chen LT. Novel multi-targeted agent against Philadelphia chromosome positive acute lymphoblastic leukemia. (poster) The 77th annual meeting of Japanese Society of Hematology 2015, Oct 16-18, Kanazawa, Japan
7. [Tsai HJ](#). National Survey of GEP-NETs in Taiwan. (Invited speaker) 2nd Annual Meeting of the Digestive Endoscopy Society of Taiwan in 2016 (DEST 2016). 2016, Aug 6, Taipei. (台大國際會議廳)

曾欽元 醫師 / 博士 / 部定教授

教育

高雄醫學院醫學系 1981年畢業
美國梅爾研究所 (Mayo Graduate School) 博士 1989年畢業

證照

中華民國醫師證書
中華民國病理專科醫師證書；美國病理專科醫師證書
臨床分子醫學專科醫師證書；臨床分子醫學品管師證書
美國田納西州 醫師執照；美國愛荷華州 醫師執照

會員

台灣醫學會；台灣病理學會；社團法人台灣分子醫學會
美國病理學院；國際泌尿病理學會

經歷

1989-1997 美國田納西大學醫學院 助理教授
1997-2001 馬偕紀念醫院 病理科 主治醫師
1999-2009 馬偕紀念醫院 癌症研究組 組長
2001-2009 馬偕紀念醫院 病理科 主任
2001-2009 馬偕紀念醫院 IRB 委員
2005-2008 馬偕紀念醫院 微生物研究組 組長
2010-2011 食藥署醫材諮議委員會委員
2006-2012 社團法人台灣分子醫學會 理事長
2009-2012 刑事警察局顧問
2012-2013 行政院衛福部食品藥物管理署 醫療器材安全委員會 副主委
2011-2014 考試院典試委員
2012-2015 分子醫學會常務監事
2013-2015 行政院衛福部食品藥物管理署 GLP 委員
2011-2016 行政院衛福部食品藥物管理署 醫療器材諮議委員會 副召集人
2013-2016 行政院衛福部食品藥物管理署 醫療器材安全委員會 委員
2013-2016 行政院衛福部食品藥物管理署 醫療器材安全評估諮議小組 委員
2009-2017 國泰綜合醫院 病理暨檢驗醫學部 部長
2009-2017 教育部部定教授 (輔仁大學醫學院 專任教授)
2011-2017 財團法人保險犯罪防制中心 諮詢委員
2017-2018 金萬林企業營運長
2006-迄今 生物醫學期刊主編 (ISSN 1999-9364)
2011-迄今 高等教育評鑑委員
2013-迄今 ISO 15189 評審委員
2013-迄今 ISO 17025 評審委員
2015-迄今 分子醫學會理事長
2015-迄今 生策會新創獎評審委員
2018-迄今 精策會 評審委員

演講

國際會議 (2004年迄今)：92場
國內之院外會議 (2004年迄今)：370場

學術論文

141篇

獎項

病理學會九十年度葉曙論文獎第一名
皮膚醫學會2017年度中華皮膚科醫學雜誌貢獻獎第一名

陳彥仰醫師

專長：一般固態腫瘤

教職：助理教授

現職：高雄長庚血液腫瘤科 主治醫師

學歷：中國醫藥學院畢業

經歷：

- 高雄長庚醫院內科部 住院醫師
- 高雄長庚血液腫瘤科 住院總醫師
- 高雄長庚血液腫瘤科 主治醫師

學會與認證：

- 中華民國癌症醫學會
- 台灣內科醫學會

論文及期刊發表：

- Chen YY, Yeh CN*, Tseng JH, Chen JS, Chen TW, Tsai CY, Cheng CT, Jan YY, Chen MF. Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing kit : A decade experience from Taiwan. Translational oncology. 2011 ; 4:328-325. (SCI; IF=3.393; Oncology 97/184)
- Jen-Shi Chen, Yen-Yang Chen, Jen-Sheng Huang, Kun-Yun Yeh, Ping-Tsung Chen, Wen-Chi Shen, Hung-Chih Hsu, Yung-Chung Lin and Hung-Ming Wang. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric cancer. 2012;15:49-55. (SCI; IF=1.897; Gastroenterology & hepatology 44/71)
- Yen-Yang Chen, Chun-Nan Yeh*, Chi-Tung Cheng, Tsung-Wen Chen, Kun-Ming Rau, Yi-Yin Jan, Miin-Fu Chen. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World journal of gastroenterology. 2011;17:2113-2119. (SCI; IF=1.897; Gastroenterology & hepatology 35/71)
- Wu chi ache, Tai-jan chiu, Meng-Chih Lin, Jui-Ling Wang, Kun ming Rau, Chen YY , Huang CH*. Pemetrexed as third-line chemotherapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) : A retrospective analysis. 2011;27:157-164
- Chen YH, Lu HI, Huang CH, Rau KM, Chiu YC, Wang YM, Chen YY, Liu CT, Li SH*. The use of trimodality treatment of locally advanced resectable esophageal squamous cell carcinoma: a single institute experience in southern Taiwan. Journal of Cancer Research and Practice. 2011; Oct 27(5): 200-210

Professor Rodney Hicks

Director: Cancer Imaging



Area of speciality
molecular imaging

Department
Centre for Cancer Imaging, Peter MacCallum Cancer Centre

Research program
Cancer Therapeutics Program

Qualifications
MB, BSc (Hons), MD, FRACP

Address
East Melbourne, Victoria, 3185, Australia

Phone
+61 3 9656 1854

Email
rod.hicks@petermac.org

Fax
+61 3 9656 1826

Education
University of Melbourne, MD, 1999
Monash University, MB BS (Hons), 1982

Grant

- ONCOGENIC SIGNALING AND CANCER THERAPY (Program Grants) awarded by NHMRC 2014 - 2018
- Metabolic regulation of ribosome biogenesis. (Project Grants) awarded by NHMRC 2013 - 2015
- PERSONALISING CARE IN RESECTABLE PANCREAS CANCER. GAP-T: A STUDY OF IMAGING AND MOLECULAR BIOMARKERS TO GUIDE TREATMENT OF PATIENTS RECEIVING PREOPERATIVE CHEMOTHERAPY FOLLOWED BY SURGERY. (Project Grants) awarded by UNIVERSITY OF SYDNEY 2012 - 2014
- Understanding Inhibition of BRAF in Melanoma (Project Grants) awarded by NHMRC 2011 - 2013
- Novel methods to predict the pharmacology and effect of anticancer drugs (Project Grants) awarded by NHMRC 2010 - 2015
- CORONET (COLLABORATIVE ORGANISATION FOR RESEARCH ON NEUROENDOCRINE TUMORS) (Translational Cancer Research Funding) awarded by VIC CANCER AGENCY 2010 - 2013
- TARGETING CELL DIVISION TO INCREASE RESPONSE TO CHEMOTHERAPY AND RADIOTHERAPY (Project Grants) awarded by NHMRC 2008 - 2010

- PARTIAL VOLUME CORRECTION IN PET IMAGING OF THE RAT BRAIN: TOWARDS AN ACCURATE QUANTIFICATION (Awards) awarded by AINSE 2008
- Mechanisms of uptake of 18F-FDG in an in vivo model of c-kit induced neoplasia (Project Grants) awarded by NHMRC 2006 - 2008
- Predictive significance of tumor hypoxia in patients with head and neck cancer treated on a randomized trial (Project Grants) awarded by NHMRC 2006 - 2008
- TARGETING 124I TO THE DNA OF TUMOURS FOR PET IMAGING AND AUGER-RADIOTHERAPY (Project Grants) awarded by NHMRC 2005 - 2007
- Molecular classification of carcinoma of unknown primary (Project Grants) awarded by NHMRC 2003 - 2005
- The Role of Glucose in Response to Cancer Treatments (Grants-in-Aid) awarded by CANCER COUNCIL VICTORIA - 2012

As head of the [Molecular Imaging and Targeted Therapeutics Laboratory](#), a major focus of Professor Rod Hicks' research has been the use of [positron emission tomography](#) (PET) to provide molecular characterisation of cancer in order to improve selection and planning of cancer treatment and monitoring response to novel targeted therapeutics. In addition, he is actively involved in [radionuclide therapy](#) with a major focus on neuroendocrine tumours. He has published over 300 peer-reviewed papers and acts as Joint Editor-in-Chief of *Cancer Imaging*. He is also an editorial board member of the *Journal of Nuclear Medicine*, the *European Journal of Nuclear Medicine and Molecular Imaging*, the quarterly *Journal of Nuclear Medicine*, *Current Medical Imaging Reviews* and *Leukaemia and Lymphoma*.